PDF herunterladen
CC BY-NC-ND 4.0 · Yearb Med Inform 2018; 27(01): 211-222
DOI: 10.1055/s-0038-1667085
Section 11: Cancer Informatics
Survey
Georg Thieme Verlag KG Stuttgart

The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources

Ewy Mathé
1   Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA
,
John L. Hays
2   Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
3   Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, USA
,
Daniel G. Stover
2   Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
,
James L. Chen
2   Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
1   Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. August 2018 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Summary

Objective: The aim is to provide a comprehensive review of state-of-the art omics approaches, including proteomics, metabolomics, cell-free DNA, and patient cohort matching algorithms in precision oncology.

Methods: In the past several years, the cancer informatics revolution has been the beneficiary of a data explosion. Different complementary omics technologies have begun coming into their own to provide a more nuanced view of the patient-tumor interaction beyond that of DNA alterations. A combined approach is beneficial to the patient as nearly all new cancer therapeutics are designed with an omics biomarker in mind. Proteomics and metabolomics provide us with a means of assaying in real-time the response of the tumor to treatment. Circulating cell-free DNA may allow us to better understand tumor heterogeneity and interactions with the host genome.

Results: Integration of increasingly available omics data increases our ability to segment patients into smaller and smaller cohorts, thereby prompting a shift in our thinking about how to use these omics data. With large repositories of patient omics-outcomes data being generated, patient cohort matching algorithms have become a dominant player.

Conclusions: The continued promise of precision oncology is to select patients who are most likely to benefit from treatment and to avoid toxicity for those who will not. The increased public availability of omics and outcomes data in patients, along with improved computational methods and resources, are making precision oncology a reality.

Keywords

Circulating tumor DNA - proteomics - metabolomics - decision support techniques - algorithms - omics integration
 

  • References

  • 1 Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res 2015; 4 (03) 256-69
    PubMedGoogle Scholar
  • 2 U.S. Food and Drug Adminstration. Paving the way for personalized medicine: FDA's role in a new era of medical product development; 2013. Available from: https://dx.advamed.org/sites/dx.advamed.org/files/resource/fda_report_on_paving_the_way_for_personalized_medicine.pdf . Accessed May 9, 2018
    PubMed
  • 3 Catenacci DV. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015; 9 (05) 967-96
    CrossrefPubMedGoogle Scholar
  • 4 Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J 2015; 6: 19
    CrossrefPubMedGoogle Scholar
  • 5 Koren G. Personalized medicine-disregarding the obvious: analysis of trends among articles published on “Personalized Medicine”. Ther Drug Monit 2015; 37 (05) 559
    CrossrefPubMedGoogle Scholar
  • 6 LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015; 521 (7553): 436-44
    PubMedGoogle Scholar
  • 7 Brower V. NCI-MATCH pairs tumor mutations with matching drugs. Nat Biotechnol 2015; 33 (08) 790-1
    CrossrefPubMedGoogle Scholar
  • 8 Bouquie R, Gregoire M, Hernando H, Azoulay C, Dailly E, Monteil-Ganiere C. , et al. Evaluation of a methotrexate chemiluminescent microparticle immunoassay: comparison to fluorescence polarization immunoassay and liquid chromatography- tandem mass spectrometry. Am J Clin Pathol 2016; 146 (01) 119-24
    CrossrefPubMedGoogle Scholar
  • 9 Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H. , et al. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 2013; 123 (09) 3740-50
    PubMedGoogle Scholar
  • 10 Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J. , et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013; 19 (22) 6322-8
    CrossrefPubMedGoogle Scholar
  • 11 Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN. , et al. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol 2013; 24 (10) 2522-6
    CrossrefPubMedGoogle Scholar
  • 12 Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A. , et al. Proteomics Tissue-based map of the human proteome. Science 2015; 347 (6220): 1260419
    CrossrefPubMedGoogle Scholar
  • 13 Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB. , et al. Explore, visualize, and analyze functional cancer proteomic data using the Cancer Proteome Atlas. Can Res 2017; 77 (21) e51-e4
    CrossrefPubMedGoogle Scholar
  • 14 Vidova V, Spacil Z. A review on mass spectrometry- based quantitative proteomics: Targeted and data independent acquisition. Anal Chim Acta 2017; 964: 7-23
    CrossrefPubMedGoogle Scholar
  • 15 Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple-reaction monitoring- mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem 2012; 58 (04) 777-81
    CrossrefPubMedGoogle Scholar
  • 16 Mao X, He J, Li T, Lu Z, Sun J, Meng Y. , et al. Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors. Sci Rep 2016; 6: 21043
    CrossrefPubMedGoogle Scholar
  • 17 Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 2017
    PubMedGoogle Scholar
  • 18 Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ. , et al. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun 2017; 8 (01) 465
    CrossrefPubMedGoogle Scholar
  • 19 Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV. , et al. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun 2017; 8: 14864
    CrossrefPubMedGoogle Scholar
  • 20 Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P. , et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 2016; 534 (7605): 55-62
    PubMedGoogle Scholar
  • 21 Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P. , et al. Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers. Cancer Res 2018
    PubMedGoogle Scholar
  • 22 Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE. , et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 2016; 166 (03) 755-65
    CrossrefPubMedGoogle Scholar
  • 23 Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB. , et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Can Ther 2006; 5 (10) 2512-21
    CrossrefPubMedGoogle Scholar
  • 24 Desiere F, Deutsch EW, Nesvizhskii AI, Mallick P, King NL, Eng JK. , et al. Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Gen Biol 2005; 6 (01) R9
    CrossrefPubMedGoogle Scholar
  • 25 Farrah T, Deutsch EW, Hoopmann MR, Hallows JL, Sun Z, Huang CY. , et al. The state of the human proteome in 2012 as viewed through PeptideAtlas. J Proteome Res 2013; 12 (01) 162-71
    CrossrefPubMedGoogle Scholar
  • 26 Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, Foster JM. , et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nuc Acids Res 2013; 41 (Database issue): D1063-9
    PubMedGoogle Scholar
  • 27 Farrah T, Deutsch EW, Kreisberg R, Sun Z, Campbell DS, Mendoza L. , et al. PASSEL: the PeptideAtlas SRMexperiment library. Proteomics 2012; 12 (08) 1170-5
    CrossrefPubMedGoogle Scholar
  • 28 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA. , et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106 (06) dju089
    PubMedGoogle Scholar
  • 29 Endris V, Stenzinger A, Pfarr N, Penzel R, Mobs M, Lenze D. , et al. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virch Archiv 2016; 468 (06) 697-705
    PubMedGoogle Scholar
  • 30 Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW. , et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol 2016; 27 (06) 1013-9
    CrossrefPubMedGoogle Scholar
  • 31 Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M. , et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gyn Onc 2016; 140 (02) 199-203
    CrossrefPubMedGoogle Scholar
  • 32 Zhang A, Sun H, Xu H, Qiu S, Wang X. Cell metabolomics. OMICS 2013; 17 (10) 495-501
    CrossrefPubMedGoogle Scholar
  • 33 LaConti JJ, Laiakis EC, Mays AD, Peran I, Kim SE, Shay JW. , et al. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. BMC Genomics 2015; 16 Suppl 1: S1
    PubMedGoogle Scholar
  • 34 Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol 2016; 17 (07) 451-9
    PubMedGoogle Scholar
  • 35 Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A. , et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 2016; 29 (01) 104-16
    CrossrefPubMedGoogle Scholar
  • 36 Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud 2015; 1 (01) a000588
    CrossrefPubMedGoogle Scholar
  • 37 Mathe EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED. , et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 2014; 74 (12) 3259-70
    CrossrefPubMedGoogle Scholar
  • 38 Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M. , et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014; 124 (01) 398-412
    CrossrefPubMedGoogle Scholar
  • 39 Armitage EG, Southam AD. Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. Metabolomics 2016; 12: 146
    CrossrefPubMedGoogle Scholar
  • 40 Liesenfeld DB, Habermann N, Owen RW, Scalbert A, Ulrich CM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev 2013; 22 (12) 2182-201
    CrossrefPubMedGoogle Scholar
  • 41 Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N. , et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007; 35 (Database issue): D521-6
    CrossrefPubMedGoogle Scholar
  • 42 Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B. , et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009; 37 (Database issue): D603-10
    CrossrefPubMedGoogle Scholar
  • 43 Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y. , et al. HMDB 3.0–The Human Metabolome Database in 2013. Nucleic Acids Res 2013; 41 (Database issue): D801-7
    PubMedGoogle Scholar
  • 44 Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 2016; 15 (07) 473-84
    CrossrefPubMedGoogle Scholar
  • 45 Wishart DS. Advances in metabolite identification. Bioanalysis 2011; 3 (15) 1769-82
    CrossrefPubMedGoogle Scholar
  • 46 Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst 2012; 137 (02) 293-300
    CrossrefPubMedGoogle Scholar
  • 47 Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130 (05) 606-25
    CrossrefPubMedGoogle Scholar
  • 48 Emwas AH. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol Biol 2015; 1277: 161-93
    PubMedGoogle Scholar
  • 49 Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol 2012; Chapter 30: Unit 30.2.1-24
    PubMedGoogle Scholar
  • 50 Vinayavekhin N, Saghatelian A. Untargeted metabolomics. Curr Protoc Mol Biol 2010; Chapter 30: Unit 30.1.1-24
    PubMedGoogle Scholar
  • 51 West JA, Beqqali A, Ament Z, Elliott P, Pinto YM, Arbustini E. , et al. A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy. Metabolomics 2016; 12: 59
    CrossrefPubMedGoogle Scholar
  • 52 Gelman SJ, Patti GJ. Profiling cancer metabolism at the ‘omic’ level: a last resort or the next frontier?. Cancer Metab 2016; 4: 2
    CrossrefPubMedGoogle Scholar
  • 53 Haznadar M, Mathe EA. Experimental and study design considerations for uncovering oncometabolites. Methods Mol Biol 2017; 1513: 37-47
    PubMedGoogle Scholar
  • 54 Dona AC, Kyriakides M, Scott F, Shephard EA, Varshavi D, Veselkov K. , et al. A guide to the identification of metabolites in NMR-based metabonomics/ metabolomics experiments. Comput Struct Biotechnol J 2016; 14: 135-53
    CrossrefPubMedGoogle Scholar
  • 55 Watson DG. A rough guide to metabolite identification using high resolution liquid chromatography mass spectrometry in metabolomic profiling in metazoans. Comput Struct Biotechnol J 2013; 4: e201301005
    PubMedGoogle Scholar
  • 56 Kind T, Fiehn O. Advances in structure elucidation of small molecules using mass spectrometry. Bioanal Rev 2010; 2 (1-4): 23-60
    CrossrefPubMedGoogle Scholar
  • 57 Grebe SK, Singh RJ. LC-MS/MS in the clinical laboratory - where to from here?. Clin Biochem Rev 2011; 32 (01) 5-31
    PubMedGoogle Scholar
  • 58 Li DW, Wang C, Bruschweiler R. Maximal clique method for the automated analysis of NMR TOCSY spectra of complex mixtures. J Biomol NMR 2017; 68 (03) 195-202
    CrossrefPubMedGoogle Scholar
  • 59 Bingol K, Bruschweiler R. Two elephants in the room: new hybrid nuclear magnetic resonance and mass spectrometry approaches for metabolomics. Curr Opin Clin Nutr Metab Care 2015; 18 (05) 471-7
    CrossrefPubMedGoogle Scholar
  • 60 Sud M, Fahy E, Cotter D, Azam K, Vadivelu I, Burant C. , et al. Metabolomics Workbench: An international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res 2016; 44 (D1): D463-70
    CrossrefPubMedGoogle Scholar
  • 61 Salek RM, Haug K, Conesa P, Hastings J, Williams M, Mahendraker T. , et al. The MetaboLights repository: curation challenges in metabolomics. Database (Oxford) 2013; 2013: bat029
    PubMedGoogle Scholar
  • 62 Menni C, Zierer J, Valdes AM, Spector TD. Mixing omics: combining genetics and metabolomics to study rheumatic diseases. Nat Rev Rheumatol 2017; 13 (03) 174-81
    CrossrefPubMedGoogle Scholar
  • 63 Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet 2015; 16 (02) 85-97
    CrossrefPubMedGoogle Scholar
  • 64 Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G. Metabolite and microbiome interplay in cancer immunotherapy. Cancer Res 2016; 76 (21) 6146-52
    CrossrefPubMedGoogle Scholar
  • 65 Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art in 2015. Front Bioeng Biotechnol 2015; 3: 23
    PubMedGoogle Scholar
  • 66 Kelder T, Conklin BR, Evelo CT, Pico AR. Finding the right questions: exploratory pathway analysis to enhance biological discovery in large datasets. PLoS Biol 2010; 8 (08) e1000472
    CrossrefPubMedGoogle Scholar
  • 67 Booth SC, Weljie AM, Turner RJ. Computational tools for the secondary analysis of metabolomics experiments. Comput Struct Biotechnol J 2013; 4: e201301003
    PubMedGoogle Scholar
  • 68 Zhang B, Hu S, Baskin E, Patt A, Siddiqui JK, Mathe EA. RaMP: A comprehensive relational database of metabolomics pathways for pathway enrichment analysis of genes and metabolites. Metabolites 2018;8(1)
    PubMedGoogle Scholar
  • 69 Siddiqui JK, Baskin E, Liu M, Cantemir-Stone CZ, Zhang B, Bonneville R. , et al. IntLIM: integration using linear models of metabolomics and gene expression data. BMC Bioinformatics 2018; 19 (01) 81
    CrossrefPubMedGoogle Scholar
  • 70 Gowda H, Ivanisevic J, Johnson CH, Kurczy ME, Benton HP, Rinehart D. , et al. Interactive XCMS Online: simplifying advanced metabolomic data processing and subsequent statistical analyses. Anal Chem 2014; 86 (14) 6931-9
    CrossrefPubMedGoogle Scholar
  • 71 Tautenhahn R, Patti GJ, Rinehart D, Siuzdak G. XCMS Online: a web-based platform to process untargeted metabolomic data. Anal Chem 2012; 84 (11) 5035-9
    CrossrefPubMedGoogle Scholar
  • 72 Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformatics 2016; 55: 14.10.1-14.10.91
    PubMedGoogle Scholar
  • 73 Xia J, Sinelnikov IV, Han B, Wishart DS. Metabo- Analyst 3.0–making metabolomics more meaningful. Nucleic Acids Res 2015; 43 (W1): W251-7
    CrossrefPubMedGoogle Scholar
  • 74 Wanichthanarak K, Fan S, Grapov D, Barupal DK, Fiehn O. Metabox: A toolbox for metabolomic data analysis, interpretation and integrative exploration. PLoS One 2017; 12 (01) e0171046
    CrossrefPubMedGoogle Scholar
  • 75 Vaniya A, Fiehn O. Using fragmentation trees and mass spectral trees for identifying unknown compounds in metabolomics. Trends Analyt Chem 2015; 69: 52-61
    CrossrefPubMedGoogle Scholar
  • 76 Wohlgemuth G, Haldiya PK, Willighagen E, Kind T, Fiehn O. The Chemical Translation Service--a web-based tool to improve standardization of metabolomic reports. Bioinformatics 2010; 26 (20) 2647-8
    CrossrefPubMedGoogle Scholar
  • 77 Rocca-Serra P, Salek RM, Arita M, Correa E, Dayalan S, Gonzalez-Beltran A. , et al. Data standards can boost metabolomics research, and if there is a will, there is a way. Metabolomics 2016; 12: 14
    CrossrefPubMedGoogle Scholar
  • 78 Spicer R, Salek RM, Moreno P, Canueto D, Steinbeck C. Navigating freely-available software tools for metabolomics analysis. Metabolomics 2017; 13 (09) 106
    CrossrefPubMedGoogle Scholar
  • 79 Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for biomarker discovery: moving to the clinic. Biomed Res Int 2015; 2015: 354671
    PubMedGoogle Scholar
  • 80 Haznadar M, Cai Q, Krausz KW, Bowman ED, Margono E, Noro R. , et al. Urinary metabolite risk biomarkers of lung cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2016; 25 (06) 978-86
    CrossrefPubMedGoogle Scholar
  • 81 Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal 2015; 107: 63-74
    CrossrefPubMedGoogle Scholar
  • 82 Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M. , et al. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics 2016; 12 (10) 149
    CrossrefPubMedGoogle Scholar
  • 83 Shaffer M, Armstrong AJS, Phelan VV, Reisdorph N, Lozupone CA. Microbiome and metabolome data integration provides insight into health and disease. Transl Res 2017; 189: 51-64
    CrossrefPubMedGoogle Scholar
  • 84 Garg N, Luzzatto-Knaan T, Melnik AV, Caraballo-Rodriguez AM, Floros DJ, Petras D. , et al. Natural products as mediators of disease. Nat Prod Rep 2017; 34 (02) 194-219
    CrossrefPubMedGoogle Scholar
  • 85 Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem 2013; 59 (04) 617-28
    CrossrefPubMedGoogle Scholar
  • 86 Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 2016; 8 (01) 42
    CrossrefPubMedGoogle Scholar
  • 87 Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535 (7610): 56-64
    PubMedGoogle Scholar
  • 88 Feng Q, Liu Z, Zhong S, Li R, Xia H, Jie Z. , et al. Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease. Sci Rep 2016; 6: 22525
    CrossrefPubMedGoogle Scholar
  • 89 Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B. , et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472 (7341): 57-63
    CrossrefPubMedGoogle Scholar
  • 90 Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X. , et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368 (17) 1575-84
    CrossrefPubMedGoogle Scholar
  • 91 Tong M, McHardy I, Ruegger P, Goudarzi M, Kashyap PC, Haritunians T. , et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 2014; 8 (11) 2193-206
    CrossrefPubMedGoogle Scholar
  • 92 Contreras AV, Cocom-Chan B, Hernandez-Montes G, Portillo-Bobadilla T, Resendis-Antonio O. Host-microbiome interaction and cancer: potential application in precision medicine. Front Physiol 2016; 7: 606
    PubMedGoogle Scholar
  • 93 Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X. , et al. Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PLoS One 2016; 11 (03) e0152126
    CrossrefPubMedGoogle Scholar
  • 94 Buescher JM, Driggers EM. Integration of omics: more than the sum of its parts. Cancer Metab 2016; 4: 4
    CrossrefPubMedGoogle Scholar
  • 95 Lempradl A, Pospisilik JA, Penninger JM. Exploring the emerging complexity in transcriptional regulation of energy homeostasis. Nat Rev Genet 2015; 16 (11) 665-81
    PubMedGoogle Scholar
  • 96 Etchegaray JP, Mostoslavsky R. Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. Mol Cell 2016; 62 (05) 695-711
    CrossrefPubMedGoogle Scholar
  • 97 Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014; 14 (09) 623-31
    CrossrefPubMedGoogle Scholar
  • 98 Mohan S, Chemi F, Brady G. Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer. Transl Lung Cancer Res 2017; 6 (04) 454-72
    CrossrefPubMedGoogle Scholar
  • 99 Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A. , et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 2014; 6 (11) 1371-86
    CrossrefPubMedGoogle Scholar
  • 100 Sparano JA, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang C. et al. Abstract GS6-03: Circulating tumor cells five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. Presented at: San Antonio Breast Cancer Symposium. 2017 Dec 3-9; San Antonio, TX. (abstract)
    PubMed
  • 101 Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101 (10) 2087-92
    CrossrefPubMedGoogle Scholar
  • 102 Garcia-Romero N, Esteban-Rubio S, Rackov G, Carrion-Navarro J, Belda-Iniesta C, Ayuso-Sacido A. Extracellular vesicles compartment in liquid biopsies: Clinical application. Mol Aspects Med 2018; 60: 27-37
    CrossrefPubMedGoogle Scholar
  • 103 Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J. , et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015; 523 (7559): 177-82
    CrossrefPubMedGoogle Scholar
  • 104 Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 2016; 126 (04) 1208-15
    CrossrefPubMedGoogle Scholar
  • 105 Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L. , et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; 359 (6378): 926-30
    CrossrefPubMedGoogle Scholar
  • 106 Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948; 142 (3-4): 241-3
    PubMedGoogle Scholar
  • 107 Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37 (03) 646-50
    PubMedGoogle Scholar
  • 108 Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987; 23 (06) 707-12
    CrossrefPubMedGoogle Scholar
  • 109 Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46 (05) 318-22
    CrossrefPubMedGoogle Scholar
  • 110 Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994; 86 (04) 774-9
    CrossrefPubMedGoogle Scholar
  • 111 Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF. , et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368 (13) 1199-209
    CrossrefPubMedGoogle Scholar
  • 112 Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF. , et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014; 370 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 113 Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153 (01) 17-37
    CrossrefPubMedGoogle Scholar
  • 114 MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31 (15) 1815-24
    CrossrefPubMedGoogle Scholar
  • 115 Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11 (10) 685-96
    CrossrefPubMedGoogle Scholar
  • 116 Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M. , et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002; 8 (12) 3761-6
    PubMedGoogle Scholar
  • 117 Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M. , et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14 (09) 985-90
    CrossrefPubMedGoogle Scholar
  • 118 Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P. , et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012; 18 (12) 3462-9
    CrossrefPubMedGoogle Scholar
  • 119 Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ. , et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7 (302): 302ra133
    CrossrefPubMedGoogle Scholar
  • 120 Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N. , et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015; 7 (313): 313ra182
    CrossrefPubMedGoogle Scholar
  • 121 Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M. , et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016; 34 (25) 2961-8
    CrossrefPubMedGoogle Scholar
  • 122 Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL. , et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 2016; 22 (04) 915-22
    CrossrefPubMedGoogle Scholar
  • 123 Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M. , et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014; 25 (10) 1959-65
    CrossrefPubMedGoogle Scholar
  • 124 Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N. , et al. Concordance of genomic alterations by next-generation sequencing (NGS) in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther 2017; 16 (07) 1412-20
    CrossrefPubMedGoogle Scholar
  • 125 Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F. , et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4 (136): 136ra68
    PubMedGoogle Scholar
  • 126 Banks KC, Mortimer SAW, Zill OA, Lanman RB, Eltoukhy H, Talasaz A. Abstract B140: Genomic profiling of over 5,000 consecutive cancer patients with a CLIA-certified cell-free DNA NGS test: Analytic and clinical validity and utility. Mol Cancer Ther 2015; 14 (12 Supplement 2): B140-B
    CrossrefPubMedGoogle Scholar
  • 127 Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C. , et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 2016; 6 (08) 838-51
    CrossrefPubMedGoogle Scholar
  • 128 Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I. , et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 2017; 32 (02) 169-84 e7
    CrossrefPubMedGoogle Scholar
  • 129 Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G. , et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21 (07) 795-801
    CrossrefPubMedGoogle Scholar
  • 130 Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C. , et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30 (06) 587-92
    CrossrefPubMedGoogle Scholar
  • 131 cobas EGFR Mutation Test v2 2016. Available from: https://www.fda.gov/Drugs/Information-OnDrugs/ApprovedDrugs/ucm504540.htm . Accessed April 12, 2018
    PubMed
  • 132 Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N. , et al. Prospective calidation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2016; 2 (08) 1014-22
    CrossrefPubMedGoogle Scholar
  • 133 Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B. , et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21 (06) 560-2
    CrossrefPubMedGoogle Scholar
  • 134 Azad AA, Volik SV, Wyatt AW, Haegert A, LeBihan S, Bell RH. , et al. Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration- resistant prostate cancer. Clin Cancer Res 2015; 21 (10) 2315-24
    CrossrefPubMedGoogle Scholar
  • 135 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M. , et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov 2015; 5 (10) 1040-8
    CrossrefPubMedGoogle Scholar
  • 136 Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E. , et al. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 2017; 12 (08) e0183949
    CrossrefPubMedGoogle Scholar
  • 137 Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I. , et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8 (346): 346ra92
    CrossrefPubMedGoogle Scholar
  • 138 Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA. , et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20 (05) 548-54
    CrossrefPubMedGoogle Scholar
  • 139 Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J. , et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9 (403): eaan2415
    CrossrefPubMedGoogle Scholar
  • 140 Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA. , et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 2017; 8 (01) 1324
    CrossrefPubMedGoogle Scholar
  • 141 Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J. , et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 2015; 6: 8760
    CrossrefPubMedGoogle Scholar
  • 142 Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM. , et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497 (7447): 108-12
    PubMedGoogle Scholar
  • 143 Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH. , et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 2017; 3 (07) 996-8
    CrossrefPubMedGoogle Scholar
  • 144 Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF. , et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371 (26) 2477-87
    CrossrefPubMedGoogle Scholar
  • 145 Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG. , et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371 (26) 2488-98
    CrossrefPubMedGoogle Scholar
  • 146 Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C. , et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014; 16 (04) 421
    CrossrefPubMedGoogle Scholar
  • 147 Ulz P, Auer M, Heitzer E. Detection of circulating tumor DNA in the blood of cancer patients: An important tool in cancer chemoprevention. Methods Mol Biol 2016; 1379: 45-68
    PubMedGoogle Scholar
  • 148 Van Roy N, Van der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J. , et al. Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients. Clin Cancer Res 2017; 23 (20) 6305-14
    CrossrefPubMedGoogle Scholar
  • 149 Stover DG, Parsons HA, Ha G, Freeman S, Barry WT, Guo H. , et al. Genomewide copy number analysis of chemotherapy resistant metastatic triple-negative breast cancer from cell-free DNA. J Clin Oncol 2018; 36 (06) 543-53
    PubMedGoogle Scholar
  • 150 Ladas I, Fitarelli-Kiehl M, Song C, Adalsteinsson VA, Parsons HA, Lin NU. , et al. Multiplexed elimination of wild-type DNA and high-resolution melting prior to targeted resequencing of liquid biopsies. Clin Chem 2017; 63 (10) 1605-13
    CrossrefPubMedGoogle Scholar
  • 151 Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S. , et al. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem 2014; 60 (03) 500-9
    CrossrefPubMedGoogle Scholar
  • 152 Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ. , et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 2018;Mar 5 [epub ahead of print]
    PubMedGoogle Scholar
  • 153 Lussier YA, Chen JL. The emergence of genome- based drug repositioning. Sci Transl Med 2011; 3 (96) 96ps35
    PubMedGoogle Scholar
  • 154 Johnson TLD, Chen JL. Opportunities for patient matching algorithms to improve patient care in oncology. JCO Clinical Cancer Informatics 2017;1(1)
    PubMedGoogle Scholar
  • 155 Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S. , et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158 (04) 929-44
    CrossrefPubMedGoogle Scholar
  • 156 Dudley JT, Chen R, Butte AJ. Matching cancer genomes to established cell lines for personalized oncology. Pac Symp Biocomput 2011; 243-52
    PubMedGoogle Scholar
  • 157 Robinson PN, Kohler S, Oellrich A, Sanger Mouse Genetics P, Wang K, Mungall CJ. , et al. Improved exome prioritization of disease genes through cross-species phenotype comparison. Genome Res 2014; 24 (02) 340-8
    CrossrefPubMedGoogle Scholar
  • 158 Wicks P, Vaughan TE, Massagli MP, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol 2011; 29 (05) 411-4
    CrossrefPubMedGoogle Scholar
  • 159 http://investors.foundationmedicine.com/news-releases/news-release-details/foundation-medicine-launches-ice-2-its-new-version-interactive (accessed May 8, 2018)
    PubMed
  • 160 Satagopan JM, Sen A, Zhou Q, Lan Q, Rothman N, Langseth H. , et al. Bayes and empirical Bayes methods for reduced rank regression models in matched case-control studies. Biometrics 2016; 72 (02) 584-95
    CrossrefPubMedGoogle Scholar
  • 161 Bragin E, Chatzimichali EA, Wright CF, Hurles ME, Firth HV, Bevan AP. , et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. Nucleic Acids Res 2014; 42 (Database issue): D993-D1000
    CrossrefPubMedGoogle Scholar
  • 162 Ma C, Ouyang J, Chen HL, Zhao XH. An efficient diagnosis system for Parkinson's disease using kernel-based extreme learning machine with subtractive clustering features weighting approach. Comput Math Methods Med 2014; 2014: 985789
    PubMedGoogle Scholar
  • 163 Chen Y, Cao W, Gao X, Ong H, Ji T. Predicting postoperative complications of head and neck squamous cell carcinoma in elderly patients using random forest algorithm model. BMC Med Inform Decis Mak 2015; 15: 44
    CrossrefPubMedGoogle Scholar
  • 164 Belciug S, Gorunescu F. Error-correction learning for artificial neural networks using the Bayesian paradigm. Application to automated medical diagnosis. J Biomed Inform 2014; 52: 329-37
    PubMedGoogle Scholar
  • 165 Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7 (01) 54-60
    CrossrefPubMedGoogle Scholar
  • 166 Mate S, Kopcke F, Toddenroth D, Martin M, Prokosch HU, Burkle T. , et al. Ontology-based data integration between clinical and research systems. PLoS One 2015; 10 (01) e0116656
    CrossrefPubMedGoogle Scholar
  • 167 Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical trial alert system on physician participation in trial recruitment. Arch Intern Med 2005; 165 (19) 2272-7
    CrossrefPubMedGoogle Scholar
  • 168 Ni Y, Wright J, Perentesis J, Lingren T, Deleger L, Kaiser M. , et al. Increasing the efficiency of trial-patient matching: automated clinical trial eligibility pre-screening for pediatric oncology patients. BMC Med Inform Decis Mak 2015; 15: 28
    CrossrefPubMedGoogle Scholar
  • 169 Gottlieb MM, Arenillas DJ, Maithripala S, Maurer ZD, Tarailo Graovac M, Armstrong L. , et al. GeneYenta: a phenotype-based rare disease case matching tool based on online dating algorithms for the acceleration of exome interpretation. Hum Mutat 2015; 36 (04) 432-8
    CrossrefPubMedGoogle Scholar
  • 170 Hansen NF. Variant calling from next generation sequence data. Methods Mol Biol 2016; 1418: 209-24
    PubMedGoogle Scholar
  • 171 Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M. , et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014; 11 (03) 333-7
    CrossrefPubMedGoogle Scholar
  • 172 Jensen MA, Ferretti V, Grossman RL, Staudt LM. The NCI Genomic Data Commons as an engine for precision medicine. Blood 2017; 130 (04) 453-9
    CrossrefPubMedGoogle Scholar
  • 173 Cook-Deegan R, Ankeny RA, Maxson Jones K. Sharing data to build a medical information commons: from Bermuda to the Global Alliance. Annu Rev Genomics Hum Genet 2017; 18: 389-415
    CrossrefPubMedGoogle Scholar
  • 174 Alterovitz G, Warner J, Zhang P, Chen Y, Ullman-Cullere M, Kreda D. , et al. SMART on FHIR Genomics: facilitating standardized clinico-genomic apps. J Am Med Inform Assoc 2015; 22 (06) 1173-8
    CrossrefPubMedGoogle Scholar
  • 175 Miller RS. CancerLinQ Update. J Oncol Pract 2016; 12 (10) 835-7
    CrossrefPubMedGoogle Scholar
  • 176 Consortium APG. AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov 2017; 7 (08) 818-31
    CrossrefPubMedGoogle Scholar
  • 177 Joly Y, Dove ES, Knoppers BM, Bobrow M, Chalmers D. Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). PLoS Comput Biol 2012; 8 (07) e1002549
    CrossrefPubMedGoogle Scholar
  • 178 Turvey C, Klein D, Fix G, Hogan TP, Woods S, Simon SR. , et al. Blue Button use by patients to access and share health record information using the Department of Veterans Affairs' online patient portal. J Am Med Inform Assoc 2014; 21 (04) 657-63
    CrossrefPubMedGoogle Scholar
  • 179 https://www.syapse.com/news/press-releases/oncology-precision-network-open-announces-data-sharing-commitments-at-vice-president-bidens-cancer-moonshot-summit (accessed May 8, 2018)
    PubMed